ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1628

Epistatic Interaction Between Solute Carrier 2A9 Genotype and Sugar-Sweetened Beverage Consumption in the Determination of Gout Risk

Tony R. Merriman1, Nicola Dalbeth2, Peter J. Gow3, Andrew Harrison4, John Highton5, Peter B. B. Jones6, Lisa K. Stamp7, Murray Cadzow8, Marilyn E. Merriman1, Ruth Topless1, Michael A. Black8, Amanda Phipps-Green1 and Caitlin M. Batt8, 1Department of Biochemistry, University of Otago, Dunedin, New Zealand, 2Medicine, University of Auckland, Auckland, New Zealand, 3Rheumatology Dept, Middlemore Hospital, Auckland, New Zealand, 4Rheumatology Unit, Hutt Hospital, Lower Hutt, New Zealand, 5Dept of Medicine, Univ of Otago Med Sch, Dunedin, New Zealand, 6Medicine, Waikato Clinical School, Waikato Hospital, Hamilton, New Zealand, 7Department of Medicine, University of Otago, Christchurch, Christchurch, New Zealand, 8University of Otago, Dunedin, New Zealand

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Gout and uric acid

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Metabolic and Crystal Arthropathies: Basic Science

Session Type: Abstract Submissions (ACR)

Background/Purpose: Consumption of drinks sweetened with sugar or high fructose corn syrup increases both serum urate levels and the risk for gout. SLC2A9 encodes a renal urate transporter that exchanges uric acid for glucose and fructose. Genetic variants in SLC2A9 explain 3.5% of the variation in serum urate levels in European Caucasian (EC) populations and are strongly associated with gout in EC and New Zealand (NZ) Maori and Pacific Island (Polynesian) people. Because SLC2A9 transports both uric acid and simple hexose sugars we tested the hypothesis that SLC2A9 genotype and sugar-sweetened beverage (SSB) consumption interact to determine the risk for gout.

Methods: NZ survey data from 1623 people with and without gout were used. Gout was determined by ARA preliminary classification criteria. SSB consumption was self-reported, including fruit juice, where one unit of drink was defined as a can or large glass. Data from the Atherosclerosis Risk in Communities (ARIC) study were also used (6003 EC controls and 153 primary gout cases determined by self-report). Two ancestral groups were studied; EC (NZ and ARIC) and NZ Polynesian. The NZ samples were genotyped for SLC2A9 single nucleotide polymorphism (SNP) rs11942223 using Taqman® technology. The ARIC samples had previously been genotyped for surrogate marker rs6449173. STATA v8.0 statistical software was used, with an interaction term included in the logistic regression analysis, derived from the ratio of the estimated odds ratio (OR) comparing exposed (≥4 SSB/day) and unexposed (<4 SSB/day) rs11942223 risk allele (T) homozygotes with the estimated OR comparing exposed and unexposed people positive for the rs11942223 protective allele (C).

Results: The risk of gout associated with consuming ≥4 SSB/day without stratification by genotype was similar to the increased genetic risk observed in the T-allele homozygous groups (Table). However the normally protective C-allele conferred a considerable increase in risk for gout in individuals exposed to ≥4 SSB/day (for example OR increased from 0.51 to 4.93 in Polynesian. The genotype by interaction term (ORI) was significant in Polynesian (ORI=5.31, P=0.043) but not in EC (ORI =5.31, P=0.087) (all adjusted by sample set, age, sex, BMI). Combining the two groups revealed significant evidence for interaction (ORI=4.74, P=0.003).

Conclusion:

When exposed to high SSB consumption individuals with the normally gout-protective allele at rs11942223 have a considerably elevated risk of gout. Our data suggest that SLC2A9-mediated uric acid transport is physiologically influenced by excess simple sugars derived from SSB, with excess SSB consumption negating the gout-risk discrimination normally mediated by rs11942223.  

Table. Risk of gout for ≥4 SSB/day stratified by genotype at SLC2A9

 

European Caucasian

Polynesian (Maori/Pacific Island)

 

Obs

OR [95% CI]1

P

Obs

OR [95% CI]

P

≥4 SSB/day group unstratified

6735

1.88 [0.87-4.07]

0.11

1020

2.02 [1.37-2.98]

4.2×10-4

T-allele homozygous, <4 SSB/day

6685

1.00

–

951

1.00

­-

C-allele positive, <4 SSB/day

0.63 [0.47-0.84]

0.002

0.51 [0.28-0.93]

0.027

T-allele homozygous, ≥4 SSB/day

1.18 [0.48-2.91]

0.71

1.82 [1.19-2.77]

0.005

C-allele positive, ≥4 SSB/day

3.91 [0.74-20.70]

0.11

4.93 [1.14-21.33]

0.033

1. ORs were adjusted by BMI, age, sex, data set.



Disclosure:

T. R. Merriman,
None;

N. Dalbeth,
None;

P. J. Gow,
None;

A. Harrison,
None;

J. Highton,
None;

P. B. B. Jones,
None;

L. K. Stamp,
None;

M. Cadzow,
None;

M. E. Merriman,
None;

R. Topless,
None;

M. A. Black,
None;

A. Phipps-Green,
None;

C. M. Batt,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/epistatic-interaction-between-solute-carrier-2a9-genotype-and-sugar-sweetened-beverage-consumption-in-the-determination-of-gout-risk/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology